Adipokines regulate mesenchymal stem cell osteogenic differentiation

Xu, Zhonghua; Xiong, Chenwei; Miao, Kaisong; Yu, Zhiyong; Zhang, Junjie; Yu, Changhong; He, Lin; Zhou, Xindie

doi:10.4252/wjsc.v15.i6.502

Cited by 6 publications

(3 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, Zhang et al [ 72 ] used IFN-γ for priming MSCs to attenuate experimental liver injury via induction of indoleamine 2,3-dioxygenase, which enhanced the protective autophagy mechanistic target of rapamycin pathway inhibition and activation of the AMPK pathway. On the same note, adipocytokines, including the proinflammatory interleukins, have been shown to contribute significantly to bone homeostasis[ 73 ]. These examples illustrate the role of a diverse array of bioactive molecules studied in experimental settings.…”

Section: Pretreatment Approaches Of Mscsmentioning

confidence: 99%

Priming mesenchymal stem cells to develop “super stem cells”

Haider

2024

World J Stem Cells

View full text Add to dashboard Cite

The stem cell pre-treatment approaches at cellular and sub-cellular levels encompass physical manipulation of stem cells to growth factor treatment, genetic manipulation, and chemical and pharmacological treatment, each strategy having advantages and limitations. Most of these pre-treatment protocols are non-combinative. This editorial is a continuum of Li et al ’s published article and Wan et al ’s editorial focusing on the significance of pre-treatment strategies to enhance their stemness, immunoregulatory, and immunosuppressive properties. They have elaborated on the intricacies of the combinative pre-treatment protocol using pro-inflammatory cytokines and hypoxia. Applying a well-defined multi-pronged combinatorial strategy of mesenchymal stem cells (MSCs), pre-treatment based on the mechanistic understanding is expected to develop “Super MSCs”, which will create a transformative shift in MSC-based therapies in clinical settings, potentially revolutionizing the field. Once optimized, the standardized protocols may be used with slight modifications to pre-treat different stem cells to develop “super stem cells” with augmented stemness, functionality, and reparability for diverse clinical applications with better outcomes.

show abstract

Section: Pretreatment Approaches Of Mscsmentioning

confidence: 99%

Priming mesenchymal stem cells to develop “super stem cells”

Haider

2024

World J Stem Cells

View full text Add to dashboard Cite

show abstract

“…High levels of leptin, as observed in obesity, can suppress osteoblast function, while adiponectin may have a protective effect on bone health. [18][19][20] Of note, individuals with diabetes often exhibit an increased risk of osteoporosis and fractures. Hyperglycemia, insulin resistance, and advanced glycation end-products (AGEs) have been implicated in impairing osteoblast function and promoting osteoclast activity, contributing to reduced bone density.…”

Section: Definition and Characteristics Of Evsmentioning

confidence: 99%

Harnessing Stem Cell-Derived Extracellular Vesicles for the Regeneration of Degenerative Bone Conditions

Jia,

Zhang,

2023

IJN

View full text Add to dashboard Cite

Degenerative bone disorders such as intervertebral disc degeneration (IVDD), osteoarthritis (OA), and osteoporosis (OP) pose significant health challenges for aging populations and lack effective treatment options. The field of regenerative medicine holds promise in addressing these disorders, with a focus on utilizing extracellular vesicles (EVs) derived from stem cells as an innovative therapeutic approach. EVs have shown great potential in stimulating biological responses, making them an attractive candidate for rejuvenating degenerative bone disorders. However, a comprehensive review summarizing the current state of this field and providing a clear assessment of EV-based therapies in degenerative bone disorders is currently deficient. In this review, we aim to fill the existing gap by outlining the current knowledge on the role of EVs derived from different types of stem cells, such as mesenchymal stem cells, embryonic stem cells, and induced pluripotent stem cells, in bone regeneration. Furthermore, we discuss the therapeutic potential of EV-based treatments for IVDD, OA, and OP. By substantiating the use of stem cell-derived EVs, we highlight their promising potential as a cell-free strategy to improve degenerative bone disorders.

show abstract

“…For large bone defects, the effect of conservative treatment is very limited. The process of bone healing or regeneration is a continuous event involving various molecules and proteins [ 3 , 4 ]. Early local chronic inflammation starts the innate immunity and vascular permeability of the body, and inflammatory cells such as macrophages and neutrophils are recruited.…”

Section: Introductionmentioning

confidence: 99%

CK1ε drives osteogenic differentiation of bone marrow mesenchymal stem cells via activating Wnt/β-catenin pathway

Yu,

Jiang,

Yin

et al. 2023

Aging

Self Cite

View full text Add to dashboard Cite

The treatment of bone defects is a difficult problem in orthopedics. At present, the treatment mainly relies on autologous or allogeneic bone transplantation, which may lead to some complications such as foreign body rejection, local infection, pain, or numbness at the bone donor site. Local injection of conservative therapy to treat bone defects is one of the research hotspots at present. Bone marrow mesenchymal stem cells (BMSCs) can self-renew, significantly proliferate, and differentiate into various types of cells. Although it has been reported that CK1ε could mediate the Wnt/β-catenin pathway, leading to the development of the diseases, whether CK1ε plays a role in bone regeneration through the Wnt/β-catenin pathway has rarely been reported. The purpose of this study was to investigate whether CK1ε was involved in the osteogenic differentiation (OD) of BMSCs through the Wnt/β-catenin pathway and explore the mechanism. We used quantitative reverse transcription-polymerase chain reaction (qRT-qPCR), Western blots, immunofluorescence, alkaline phosphatase, and alizarin red staining to detect the effect of CK1ε on the OD of BMSCs and the Wnt/β-catenin signaling pathway. CK1ε was highly expressed in BMSCs with OD, and our study further demonstrated that CK1ε might promote the OD of BMSCs by activating DLV2 phosphorylation, initiating Wnt signaling downstream, and activating β-catenin nuclear transfer. In addition, by locally injecting a CK1ε-carrying adeno-associated virus (AAV5- CK1ε) into a femoral condyle defect rat model, the overexpression of CK1ε significantly promoted bone repair. Our data show that CK1ε was involved in the regulation of OD by mediating Wnt/β-catenin. This may provide a new strategy for the treatment of bone defects.

show abstract

Adipokines regulate mesenchymal stem cell osteogenic differentiation

Cited by 6 publications

References 133 publications

Priming mesenchymal stem cells to develop “super stem cells”

Priming mesenchymal stem cells to develop “super stem cells”

Harnessing Stem Cell-Derived Extracellular Vesicles for the Regeneration of Degenerative Bone Conditions

CK1ε drives osteogenic differentiation of bone marrow mesenchymal stem cells via activating Wnt/β-catenin pathway

Contact Info

Product

Resources

About